Comparative efficacy and safety of moxifloxacin versus omadacycline in the treatment of adult Mycoplasma pneumoniae pneumonia
Liu Yanyan
Xue Tianjiao
Zhang Yuanyuan
Tang Yanfen
Wang Yu
Abstract：Objective To compare the efficacy and safety of moxifloxacin and omadacycline in the treatment of adult Mycoplasma pneumoniae pneumonia(MPP).Methods The clinical data of 139 adult MPP patients admitted to Beijing Ditan Hospital,Capital Medical University,from August to December 2024 were retrospectively collected.Among them,73 cases were treated with omadacycline(observation group)and 66 cases with moxifloxacin(control group).The clinical indicators,antipyretic time,symptom remission rate,improvement of pulmonary imaging and safety of the two groups were analyzed.Results After treatment,the levels of white blood cell count,neutrophil/lymphocyte ratio,C-reactive protein,procalcitonin,serum amyloid A and interleukin-6 in both groups were significantly better than those before treatment(all P<0.05),while there were no statistically significant differences between the two groups(all P>0.05).The antipyretic time in the observation group was shorter than that in the control group[(1.3±0.5)d vs(2.1±0.8)d](P=0.02).There was no significant difference in the total effective rate between the observation group and the control group[91.8％(67/73)vs 90.9％(60/66)](P=0.85).After 1 and 4 weeks of treatment,there were no significant differences in the imaging absorption rate between the two groups(both P>0.05).During the treatment period,the incidence of adverse reactions in the observation group was lower than that in the control group[2.7％(2/73)vs 12.1％(8/66)](χ2=7.93,P<0.01).Conclusion Omadacycline has comparable efficacy to moxifloxacin in the treatment of adult MPP,with the advantage of better safety.
Keywords：Mycoplasma pneumoniae pneumoniaMoxifloxacinOmadacyclineSafety
Publication Date：2026-02-18
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 199-202 )